ML
EGRX

McAdam LLC’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

McAdam LLC’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100
Closed -$8K – 749
2018
Q2 		$8K Sell
100
-300
-75% -$18.9K ﹤0.01% 354
2018
Q1 		$21K Buy
+400
New +$23.3K 0.01% 239

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

McAdam LLC's EGRX Position: Q3 2018 in Review

McAdam LLC sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2018, closing a stake of 100 shares — an estimated $8K sold.

McAdam LLC first reported a position in EGRX in Q1 2018 and held it in 2 quarters. The position peaked at $21K in Q1 2018. 189 funds tracked by Wall St. Rank hold EGRX as of Q3 2018.

  • McAdam LLC reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • McAdam LLC sold 100 Eagle Pharmaceuticals, Inc. shares in Q3 2018, an estimated $8K.
  • McAdam LLC first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2018 and held it in 2 quarters.
  • McAdam LLC's Eagle Pharmaceuticals, Inc. position peaked at $21K in Q1 2018.
  • 189 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2018.

Based on McAdam LLC's 13F filing for Q3 2018, filed 10 Oct 2018.